Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
NCT05007145Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05007145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05007145.